Dyslipidemia and peripheral arterial disease

Simple item page
dc.contributor.authorYadav, Ajayen_US
dc.contributor.authorSawant, Viveken_US
dc.contributor.authorBedi, Varinder Singhen_US
dc.contributor.authorYadav, Kanupriyaen_US
dc.date.accessioned2025-05-09T07:17:54Z
dc.date.available2025-05-09T07:17:54Z
dc.date.issued2024-03
dc.description.abstractPeripheral arterial disease (PAD) affects 12 % of adult population and is increasing globally and in India. Pe- ripheral arterial disease when associated with atherosclerosis in two or more other arterial beds such as coronary artery disease (CAD), mesenteric/renal artery and cerebrovascular disease (CVD), is known as polyvascular disease. The Reduction of Atherothrombosis for Continued Health (REACH) registry reported that 1 out of 6 patients had multi-vascular bed involvement. Progression of PAD to critical limb ischaemia (CLI) is seen in 1 % of affected patients per year, but patients who progress to CLI may have a 10- to 15-fold increased risk of car- diovascular death. The 2019 ECS/EAS guidelines for the management of dyslipidaemias have suggested that for primary or secondary prevention in very high risk, patients should follow a therapeutic regimen that achieves >50 % LDL-C reduction from baseline and an LDL-C goal of <55 mg/dl. High Intensity Statin is mainstay of treatment but optimal management is inadequate. Statin treatment reduces all-cause mortality by 39 %, CV death by 41 %, CV outcomes by 34 %, ischaemic stroke by 28 %, acute limb ischaemia by 30 % and amputations by 35 %. Ezetimibe when added to statins in IMPROVE-IT trial, showed significant reduction of MACE. PCSK9 inhibitor (FOURIER TRIAL) showed reduction in primary end point in PAD vs Non PAD patients (3.5 % vs 1.6 %). There is a critical need for an Indian multi-disciplinary task force for research on the direct impact of lipid- lowering agents on limb salvage rates and major limb-related events in PAD patients.en_US
dc.identifier.affiliationsInstitutions: Sir Ganga Ram Hospital, Indiaen_US
dc.identifier.affiliationsInstitutions: Sir Ganga Ram Hospital, Indiaen_US
dc.identifier.affiliationsInstitutions: Sir Ganga Ram Hospital, Indiaen_US
dc.identifier.affiliationsMahajan Imaging and Labs, Indiaen_US
dc.identifier.citationYadav Ajay, Sawant Vivek, Bedi Varinder Singh, Yadav Kanupriya . Dyslipidemia and peripheral arterial disease. Indian Heart Journal. 2024 Mar; 76(1): 86-89en_US
dc.identifier.issn0019-4832
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/242773
dc.languageenen_US
dc.publisherElsevieren_US
dc.relation.issuenumber1en_US
dc.relation.volume76en_US
dc.source.urihttps://doi.org/10.1016/j.ihj.2024.01.010en_US
dc.subjectDyslipidaemiaen_US
dc.subjectPeripheral arterial diseaseen_US
dc.subjectEzetimibeen_US
dc.subjectPolyvascular diseaseen_US
dc.subjectLDL-C goal of <55 mg/dlen_US
dc.titleDyslipidemia and peripheral arterial diseaseen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ihj2024v76s1p86.pdf
Size:
370.99 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Heart Journal